Mandate

Vinge advises SEB Kort Bank AB in connection with its acquisition of Lufthansa AirPlus Servicekarten GmbH

June 21, 2023 M&A

SEB Kort Bank AB ("SEB Kort"), a wholly-owned subsidiary within the SEB Group, has entered into an agreement with Lufthansa Group to acquire all shares in Lufthansa AirPlus Servicekarten GmbH ("AirPlus").

Together, SEB Kort and AirPlus will become a leading European player in the corporate payments sector. For a cash consideration of EUR 450 million, the transaction will provide SEB Kort with additional scale, a strong position for further growth in Europe, and a modern IT platform. In addition, the transaction is expected to result in synergies and also complement SEB's broader ambitions in the corporate business in the DACH region (Germany, Austria, and Switzerland) and northern Europe.

In connection with the transaction, Vinge has acted as local counsel for SEB Kort and assisted with Swedish corporate and regulatory matters.

The transaction is, inter alia, subject to approvals from governmental authorities.

Vinge's team consisted of Daniel Rosvall and Viktor Lennartsson (M&A) as well as Caroline Krassén (Financial Services).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025